Splenomegaly Clinical Trial
Official title:
Estimation of Spleen Size by Medical Residents With Hand Carried Ultrasound
In internal medicine, assessment of spleen size on physical examination is an extremely important part of the overall evaluation of patients with many illnesses. Examination of the spleen is also one of the core competencies that the investigators expect the students and residents to learn as part of their training. Unfortunately, the sensitivity and specificity of examination of the spleen at the bedside is not very good. The investigators wish to determine if medical residents can be taught to use hand carried ultrasound to accurately assess spleen size. Doing so would make physical examination of the spleen obsolete and transform training objectives for medical trainees.
The diagnosis of splenomegaly is extremely important in managing patients with blood
disorders and other medical conditions, such as cirrhosis. The ability to recognize an
enlarged spleen in a timely manner can impact patient outcomes. Although the physical exam
can be confidently used to diagnosis massive enlargement of the spleen, evaluating lesser
degrees of splenomegaly at the bedside proves more difficult. In current practice, the gold
standard for diagnosis of splenomegaly is the conventional abdominal ultrasound. The
prevalence of splenomegaly in patients with blood conditions and other medical disorders is
relatively high. Therefore, the demand for abdominal ultrasound is growing and similarly the
cost of caring for patients with these conditions.
In addition, examination of the spleen is one of the core competencies that the
investigators expect the students and residents to learn as part of their training. This
physical diagnosis maneuver is frequently used to examine residents at the Royal College
level and determine their fitness to practice. Unfortunately, the sensitivity and
specificity of examination of the spleen at the bedside is not very good.
With the introduction of hand carried ultrasound (HCU) devices, rapid bedside assessment of
a patient is now possible. The Visual scan (VScan) (GE Healthcare, USA) allows for 2D
imaging on a 3.5 inch display and has shown to have comparable image quality to standard
ultrasound for some applications. The VScan and other HCU have been used at point of care to
evaluate a number of conditions and can greatly impact treatment decisions in medical
patients at the bedside. The ability to recognize splenomegaly in a timely manner can impact
patient outcomes. In addition, the use of this technology could significantly impact
training standards for students and residents.
It remains unclear whether bedside evaluation with the VScan is able to accurately measure
spleen size. The investigators conducted an extensive literature review and the
investigators were unable to find any studies attempting to accurately assess spleen size
with HCU. The investigators recently demonstrated that trained ultrasonographers can
reliably assess spleen size at the bedside using a VScan. The current study aims to
determine the diagnostic accuracy of the VScan when used by medical residents who have been
trained in its use, in patients with varying degrees of splenomegaly, including normal
spleen size. If the investigators can show that medical residents can accurately
characterize spleen size at the bedside with a hand carried device, the next stage of the
study will be to determine how the investigators can integrate HCU with physical examination
at the bedside to assess spleen size.
Design, Specification of Endpoints, and Procedures:
The investigators propose a validation study in 50 patients who have medical conditions that
may result in varying degrees of splenomegaly (including normal spleen size) and who are
looked after in the hematology clinics at Vancouver General Hospital (VGH). Patients will be
recruited based on information provided in the charts in the private offices of
hematologists at VGH.
The investigators will also enroll 20 first year medical residents. First year residents
will be sent a letter by email describing the study.
Each medical resident will undergo a one hour training sessions by an ultrasonographer
regarding the use of HCU to assess spleen size. At the end of the session, they will be
evaluated by the sonographer to make sure they know how to use the HCU to acquire images of
the spleen. If they are not proficient they will undergo a subsequent one hour training
session. On a separate day, a trained ultrasonographer will perform a conventional
ultrasound on each patient to accurately measure their spleen size. This information will be
provided to the patients hematologist. Subsequently residents will attempt to measure the
size of the patient's spleen using the VScan. Each patient will be scanned 5 times by 5
different residents. Each resident will be blinded as to the patient's underlying medical
conditions and the results of previous scans. Variables of interest include: adequacy of the
study, findings on 2D imaging, overall diagnosis of presence of splenomegaly, confidence
level in diagnosis and time to complete test.
The goal is to determine if medical residents can use a hand carried ultrasound device to
accurately assess spleen size.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Not yet recruiting |
NCT06345495 -
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
|
Phase 2 | |
Completed |
NCT04430881 -
A National Study in Patients With Unexplained Splenomegaly
|
||
Completed |
NCT01948076 -
Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination
|
N/A | |
Completed |
NCT04716166 -
Incentive Spirometry and Upper Abdominal Laparoscopic Surgery
|
N/A | |
Recruiting |
NCT03801434 -
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
|
Phase 2 | |
Terminated |
NCT02421354 -
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
|
Phase 2 | |
Recruiting |
NCT05641103 -
PREDIGA 2: Spanish Acronym of "Educational and Diagnostic Project for Gaucher and ASMD"
|
||
Completed |
NCT01810419 -
Ultrasound Estimation of Spleen Size
|
N/A | |
Recruiting |
NCT01201655 -
Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
|
N/A | |
Active, not recruiting |
NCT02871219 -
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
|
Phase 2 | |
Completed |
NCT00006148 -
Spleen Size in Peripheral Blood Stem Cell Donors
|
N/A | |
Withdrawn |
NCT01331642 -
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
|
||
Withdrawn |
NCT02298699 -
Biomarker for Sly Disease (MPS VII) (BioSly)
|
||
Withdrawn |
NCT02298634 -
Biomarker for Farber Disease (BioFarber)
|
||
Terminated |
NCT02730884 -
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
|
Phase 2 | |
Terminated |
NCT02463669 -
The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
|